title: [Correlation between the effectiveness of atypical antipsychotics and dopamine D3 receptor polymorphism in schizophrenia].
abstract: OBJECTIVE
  Numerous relevant variants of dopamine receptors have been identified in schizophrenia. The Ser9Gly gene polymorphism of dopamine D3 receptor is known as a susceptibility factor for the disease. In addition, it has a role in the modification of therapeutic effect of antipsychotics. In this naturalistic study the authors investigated the relationship between this polymorphism and the therapeutic response to atypical antipsychotics.
  
  
  METHODS
  75 patients with schizophrenia according to DSM-IV and 45 healthy controls were recruited. The patients were divided to responder and nonresponder subgroups, cut-off: > 20 point improvement in Global Assessment of Functioning. By polymerase chain reaction the genotype of dopamine D3 receptor of every participant was determined.
  
  
  RESULTS
  The Ser9Ser genotype of dopamine D3 receptor was more frequent in the nonresponder subgroup (64%, p = 0.0018). The Ser9 allele was overrepresented among nonresponder patients (82%, p = 0.0172).
  
  
  CONCLUSIONS
  Based on our results, the worse therapeutic response to atypical antipsychotics is associated with Ser9 variant of dopamine D3 receptor.
authors.affiliation: Szegedi Tudományegyetem, Pszichiátriai Klinika, H-6725 Szeged, Semmelweis u. 6. szekeres@nepsy.szote.u-szeged.hu
authors.forename: György
authors.initials: G
authors.lastname: Szekeres
authors.forename: Anna
authors.initials: A
authors.lastname: Juhász
authors.forename: Szabolcs
authors.initials: S
authors.lastname: Kéri
authors.forename: Agnes
authors.initials: A
authors.lastname: Rimanóczy
authors.forename: István
authors.initials: I
authors.lastname: Szendi
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szabó
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Janka
mesh_terms: D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000235:genetics*; D050637:Receptors, Dopamine D3; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*
chemical_list: D014150:Antipsychotic Agents; C493593:DRD3 protein, human; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3